Valuation: Biocorrx Inc

Market Cap 7.55M 6.57M 6.13M 5.63M 10.61M 720M 10.8M 72.28M 28.31M 359M 28.38M 27.75M 1.18B P/E 2024
-0.78x
P/E 2025 -1.56x
Enterprise Value 9.56M 8.3M 7.75M 7.12M 13.42M 911M 13.66M 91.42M 35.81M 454M 35.89M 35.1M 1.5B EV / Sales 2024
1,004x
EV / Sales 2025 11.4x
Free-Float
38.64%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 58 2020-11-08
President 77 2024-01-04
Director TitleAgeSince
Director/Board Member 58 2013-03-06
Chairman 57 -
Director/Board Member 77 2019-02-28
Change 5-day change 1-year change 3-year change Capi.($)
-15.84%+6.09% - - 7.55M
+0.89%-1.49%+71.64%+41.92% 133B
+0.45%+3.84%+11.39%+49.43% 87.16B
+0.56%+1.18%+7.91%+57.59% 28.85B
-0.53%+0.02%+34.48%+69.65% 25.72B
+1.49%+6.97%-9.23%-16.55% 21.85B
-2.21%+2.54%+54.93%+235.64% 20.51B
-1.24%+0.23%+69.76%+133.21% 15.41B
-1.91%+1.13%+2.35%-1.62% 14.98B
+0.92%+2.23%+3.58%-5.10% 13.55B
Average -1.86%+3.25%+27.42%+62.69% 40.14B
Weighted average by Cap. +0.29%+1.64%+38.03%+54.75%

Financials

2024 2025
Net sales 7.66K 6.66K 6.22K 5.71K 10.77K 731K 10.95K 73.33K 28.72K 364K 28.79K 28.15K 1.2M 797K 693K 647K 594K 1.12M 75.99M 1.14M 7.63M 2.99M 37.9M 2.99M 2.93M 125M
Net income -5.11M -4.44M -4.14M -3.8M -7.17M -487M -7.3M -48.85M -19.13M -243M -19.18M -18.75M -801M -3.44M -2.99M -2.79M -2.56M -4.83M -328M -4.92M -32.91M -12.89M -164M -12.92M -12.64M -539M
Net Debt 2.72M 2.36M 2.21M 2.02M 3.82M 259M 3.88M 26.01M 10.19M 129M 10.21M 9.98M 426M 2M 1.74M 1.62M 1.49M 2.81M 191M 2.86M 19.15M 7.5M 95.13M 7.52M 7.35M 314M
Logo Biocorrx Inc
BioCorRx Inc. is an addiction treatment solutions company. The Company is engaged in offering treatment for substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app, along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight-loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. It also controls BioCorRx Pharmaceuticals Inc., a clinical-stage drug development subsidiary, which is seeking FDA approval for BICX104, an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders. It is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.
Employees
-